SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort.
PLoS Biol
; 20(2): e3001531, 2022 02.
Article
in En
| MEDLINE
| ID: mdl-35143473
ABSTRACT
Identifying the potential for SARS-CoV-2 reinfection is crucial for understanding possible long-term epidemic dynamics. We analysed longitudinal PCR and serological testing data from a prospective cohort of 4,411 United States employees in 4 states between April 2020 and February 2021. We conducted a multivariable logistic regression investigating the association between baseline serological status and subsequent PCR test result in order to calculate an odds ratio for reinfection. We estimated an odds ratio for reinfection ranging from 0.14 (95% CI 0.019 to 0.63) to 0.28 (95% CI 0.05 to 1.1), implying that the presence of SARS-CoV-2 antibodies at baseline is associated with around 72% to 86% reduced odds of a subsequent PCR positive test based on our point estimates. This suggests that primary infection with SARS-CoV-2 provides protection against reinfection in the majority of individuals, at least over a 6-month time period. We also highlight 2 major sources of bias and uncertainty to be considered when estimating the relative risk of reinfection, confounders and the choice of baseline time point, and show how to account for both in reinfection analysis.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Reinfection
/
COVID-19
/
Antibodies, Viral
Type of study:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adolescent
/
Adult
/
Aged
/
Humans
/
Middle aged
Country/Region as subject:
America do norte
Language:
En
Journal:
PLoS Biol
Journal subject:
BIOLOGIA
Year:
2022
Type:
Article
Affiliation country:
United kingdom